Prescriber Scope of Practice for General Psychiatry in Michigan

If you’re a psychiatrist or psychiatric NP considering telehealth—or already practicing remotely—you’ve probably asked yourself: Can I legally prescribe Adderall to a new patient I’ve only seen on video? What about Xanax? Buprenorphine?

The short answer as of early 2026: Yes, you can—for now. But the rules are complex, constantly evolving, and vary significantly by state. And ‘for now’ is the key phrase, because the DEA is finalizing permanent telehealth prescribing regulations that will reshape how you practice.

Let’s cut through the confusion. This guide explains the current federal DEA rules, what’s changing in 2026, and the state-specific regulations you need to know if you practice in California, Texas, Florida, New York, Pennsylvania, or Illinois. We’ll also cover the critical differences between psychiatrist and PMHNP scope of practice when it comes to controlled substances.

Where Things Stand Right Now: DEA’s Temporary Extension Through 2026

The federal government has extended COVID-era telehealth flexibilities for controlled substance prescribing through December 31, 2026. This means you can continue prescribing Schedule II–V medications (stimulants, benzodiazepines, buprenorphine, etc.) via telemedicine to new patients without an initial in-person exam—as long as you conduct a proper evaluation via real-time audio-video consultation.

This extension, announced by HHS and DEA in January 2026, prevents care disruptions while permanent rules are finalized. But it’s the fourth temporary extension, and permanent regulations are coming. The Ryan Haight Act’s requirement for an in-person visit before prescribing controlled substances online is still technically law—it’s just been suspended under these emergency exceptions.

What this means for your practice today:

• You can initiate ADHD treatment with stimulants via video consultation
• You can prescribe benzodiazepines for anxiety disorders to new telehealth patients
• You can start patients on buprenorphine for opioid use disorder without seeing them in person
• You must use interactive, real-time audio-visual technology (not just phone calls, except for specific buprenorphine cases)
• You still need proper licensure, DEA registration, and must follow all other prescribing standards

The catch: If a patient has ever been seen in person by any provider (not necessarily you), there’s no federal restriction on telehealth prescribing of controlled substances for that patient. The current flexibility specifically addresses new patients who’ve never had an in-person evaluation.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What’s Coming: DEA’s Proposed Permanent Rules

The DEA has proposed three new rules to replace temporary extensions. Here’s what psychiatric providers need to know:

1. Special Telemedicine Registration for Schedule II Prescribing

The DEA is creating a Special Telemedicine Prescriber Registration that would allow certain qualified providers to prescribe controlled substances to new patients via telehealth without ever requiring an in-person exam.

For psychiatrists, this is huge: Board-certified psychiatrists would be eligible to obtain this special registration for Schedule II substances (including stimulants like Adderall). This means you could continue building a telehealth-only practice for ADHD and other psychiatric conditions requiring Schedule II medications—legally and permanently.

The special registration would require:

• Additional DEA registration fees
• Compliance with enhanced monitoring requirements
• Integration with a national PDMP system
• Annual reporting on telehealth controlled substance prescribing

For platforms: Online telehealth companies would be required to register with the DEA for the first time, creating accountability for how they facilitate prescriptions. This is the DEA’s response to concerns about overprescribing by some telehealth startups.

2. Expanded Buprenorphine Access via Telehealth

If you provide medication-assisted treatment for opioid use disorder, the proposed rule would allow you to prescribe buprenorphine via telehealth (including audio-only) for up to 6 months before requiring an in-person visit. This expands on current practice and recognizes how telehealth has improved access to addiction treatment.

After 6 months, patients would need at least one in-person evaluation to continue buprenorphine treatment.

3. What About PMHNPs?

The proposed rules don’t explicitly address nurse practitioners in the same way as board-certified psychiatrists. PMHNPs would likely be eligible for the special registration for Schedule III–V substances, but Schedule II prescribing authority via the special registration appears limited to certain physician specialties (psychiatry, hospice/palliative care, pediatrics for specific uses).

This means psychiatric NPs may face more restrictions than psychiatrists under the new permanent rules, particularly for stimulant prescribing via telehealth to new patients. State scope-of-practice laws already create this disparity—more on that below.

The Economics Reality: Why Telehealth Platforms Make Sense

Let’s talk about patient acquisition cost—because this is where many providers get burned when they try to go solo with telehealth.

The myth: You can acquire psychiatric patients cheaply through DIY marketing—maybe $30-50 per patient through Google Ads or directory listings.

The reality: Acquiring a qualified psychiatric patient who actually books and shows up typically costs $200-500+ when you factor in:

• SEO agency or consultant fees ($1,500-3,000/month minimum)
• 6-12 months before SEO generates meaningful patient flow
• Google Ads costs ($15-40+ per click for mental health keywords, with most clicks not converting)
• Psychology Today or Zocdoc monthly fees plus per-booking charges
• Staff time to handle and qualify leads
• No-show rates from cold marketing leads
• Failed campaigns and testing costs

A realistic all-in cost per booked patient through your own PPC campaigns is $200-400+. And that assumes you have the expertise to run effective campaigns—most providers don’t.

Compare that to platforms like Klarity Health, which use a pay-per-appointment model. You pay a standard fee only when a pre-qualified patient actually books with you. No upfront marketing spend. No monthly subscriptions. No wasted ad budget on clicks that don’t convert. No technical platform costs.

The value proposition is simple:

• Pre-qualified patients already matched to your specialty and availability
• Built-in telehealth infrastructure (no separate platform fees)
• Both insurance and cash-pay patient flow
• You control your schedule—only pay when you see patients
• Guaranteed ROI versus gambling on marketing channels

For most providers—especially those starting out or scaling up—this removes the financial risk entirely. Instead of spending $3,000-5,000/month on marketing with uncertain results, you pay only for actual appointments.

State-by-State Breakdown: Where the Real Complexity Lives

Federal DEA rules set the floor, but states can impose stricter requirements. Here’s what you need to know for six major markets:

California: Telehealth-Friendly with Strong PDMP Requirements

Good news: California allows telehealth prescribing of controlled substances with no special restrictions beyond federal law. A video consultation establishes a valid patient relationship—no in-person visit required.

What you must do:

• Check the CURES PDMP before prescribing Schedule II–IV substances to a patient for the first time
• Re-check CURES every 4 months during ongoing controlled substance treatment
• Use electronic prescribing for all prescriptions (mandated since January 2022)
• Maintain California medical license (or CA APRN license for PMHNPs)

For PMHNPs: California is transitioning to full practice authority. Experienced NPs (with 3+ years in approved settings) can now practice in group settings without physician supervision. By 2026, they’ll be able to open independent practices. This makes California increasingly attractive for psychiatric NPs.

The licensing catch: California recently joined the Interstate Medical Licensure Compact (IMLC), which will make it easier for out-of-state physicians to get licensed. But you still need a full California license to treat California patients—there’s no special telehealth registration.

Texas: Complex Rules and Strict NP Limitations

The landscape: Texas modernized telehealth in 2017, removing the in-person requirement for establishing care via video. Mental health was actually exempt from the old restrictions, so telepsychiatry has been well-established.

Critical limitations for NPs:

• Texas PMHNPs cannot prescribe Schedule II controlled substances for outpatient psychiatric care—period
• Schedule II authority for NPs is limited to hospital (≥24-hour admission), ER, or hospice settings only
• This means any Texas patient needing ADHD medications must see a psychiatrist, not an NP

For all providers:

• Cannot prescribe controlled substances for chronic pain via telehealth without an in-person exam
• Must check the Texas PMP before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol
• NPs must practice under physician supervision and delegation agreements

Platform implications: If you’re building a telehealth service in Texas, you need physicians to handle any Schedule II prescriptions. Many platforms pair MDs and NPs to cover different patient needs.

Florida: Psychiatric Exception to Strict Telehealth Rules

Florida has one of the most detailed—and restrictive—telehealth laws in the country, but it includes a critical exception for psychiatry.

The rule: Schedule II controlled substances cannot be prescribed via telehealth EXCEPT for:

1. Psychiatric disorder treatment
2. Inpatient hospital care
3. Hospice care
4. Nursing home resident care

What this means: You can prescribe Adderall via telehealth for ADHD (psychiatric condition = allowed). You cannot prescribe oxycodone via telehealth for chronic pain (not allowed). Document the psychiatric indication clearly in your notes.

Florida’s unique telehealth registration: Out-of-state providers can register to provide telehealth to Florida patients without getting a full Florida license. However, this registration still subjects you to Florida’s prescribing rules, and you must:

• Carry malpractice insurance
• Designate a Florida agent
• Not open a physical clinic in Florida

Other requirements:

• Check E-FORCSE PDMP before prescribing any controlled substance to patients age 16+
• Use electronic prescribing (mandated since 2021)
• If prescribing controlled substances for chronic pain, designate yourself as a controlled substance prescriber on your DOH profile

For PMHNPs: Florida does not allow independent practice for psychiatric NPs. You must have a collaborative agreement with a supervising physician.

New York: Strong PDMP Mandates, Emerging NP Independence

The framework: New York allows telehealth prescribing of controlled substances without special restrictions. Video consultation establishes a valid patient relationship.

Compliance requirements:

• Mandatory PMP check before prescribing any Schedule II, III, or IV controlled substance (NY’s I-STOP law)
• Electronic prescribing required for all prescriptions—controlled and non-controlled—since 2016
• Full New York medical license required (no IMLC membership yet, so out-of-state licensing is slower)

For PMHNPs: New York modernized NP practice in 2022. Psychiatric NPs with more than 3,600 clinical hours can practice independently without a physician collaborative agreement. Those with fewer hours still need a supervising physician on record.

This makes New York attractive for experienced PMHNPs who want to build independent telehealth practices.

Reimbursement bonus: New York has strong telehealth parity laws and made audio-only mental health services permanently reimbursable by Medicaid—though for controlled substance prescribing, use video for new patients.

Pennsylvania: Legal Gray Zone with Strict NP Requirements

The situation: Pennsylvania has no comprehensive telehealth statute yet (multiple bills have stalled). Telehealth happens under general medical board authority.

What’s allowed:

• Video consultation can establish a valid patient relationship
• No specific prohibition on telehealth prescribing of controlled substances
• Follow federal DEA rules and standard of care

Compliance musts:

• Check PA PDMP before prescribing opioids or benzodiazepines (and periodically during treatment)
• Electronic prescribing required for Schedule II–V controlled substances since 2019

For PMHNPs: Pennsylvania requires collaborative agreements with at least one physician (effectively two for full prescriptive authority). NPs can prescribe:

• Schedule II up to 30-day supply
• Schedule III-IV up to 90-day supply
• No independent practice pathway

The licensing angle: Pennsylvania joined the IMLC in 2021, making it easier for out-of-state physicians to get licensed. But out-of-state providers still need full PA licensure—no special telehealth registration.

Illinois: Full Practice Authority with Medication-Specific Limits

The setup: Illinois has embraced telehealth with parity laws and clear guidance that standard of care applies equally to remote and in-person care.

What’s permitted:

• Video consultation establishes patient relationship
• No in-person requirement for prescribing
• No blanket prohibition on telehealth controlled substance prescribing

Compliance requirements:

• Check IL PMP each time before prescribing opioids (encouraged for all controlled substances)
• Electronic prescribing required for all controlled substances since January 2023
• Document PMP checks in patient records

For PMHNPs: Illinois offers a pathway to full practice authority through the APRN-FPA license (requires 4,000 clinical hours and additional training).

The catch: Even NPs with full practice authority must enter a ‘consultation relationship’ with a physician to prescribe benzodiazepines or Schedule II opioids, limited to 30-day supplies. The law’s wording is somewhat ambiguous about whether this applies to Schedule II stimulants—seek clarification from the Illinois Board of Nursing if you’re prescribing ADHD medications as an NP.

Psychiatrists: Full prescribing authority with no additional limitations beyond federal law and PDMP requirements.

Psychiatrist vs. PMHNP: Scope of Practice Reality Check

Here’s the truth: Your provider type fundamentally affects what you can prescribe and how independently you can practice.

Psychiatrists (MD/DO)

Scope: Full independent practice authority in all 50 states. No supervision requirements. Complete prescribing authority for all controlled substances consistent with DEA rules.

Multi-state practice: Can obtain licenses in multiple states and maintain DEA registrations in each. IMLC membership (available in many states including Texas, Illinois, Pennsylvania) streamlines the licensing process.

Platform implications: Psychiatrists have the broadest flexibility to join telehealth platforms and treat patients across state lines (with appropriate licensure).

Psychiatric Mental Health Nurse Practitioners (PMHNPs)

Scope: Varies dramatically by state. Three general categories:

Full Practice States (e.g., New York after 3,600 hours):

• Can evaluate, diagnose, and prescribe independently
• No physician supervision required
• Same prescribing authority as psychiatrists (within nursing scope)

Reduced Practice States (e.g., Pennsylvania, Ohio):

• Can do most psychiatric work with collaborative agreement
• Physician doesn’t need to be on-site but must have formal oversight
• May have limits on Schedule II prescribing (30-90 day supplies)

Restricted Practice States (e.g., Texas, Florida):

• Require physician supervision or delegation
• May prohibit certain controlled substance prescribing entirely (Texas: no outpatient Schedule II)
• Limited to specific practice settings

Critical for telehealth platforms: When recruiting PMHNPs, you must account for their state’s practice authority. An NP who can work completely independently in California cannot do the same in Texas without a supervising physician arrangement.

Additional Federal Requirements You Can’t Ignore

Beyond DEA telehealth rules and state laws, don’t forget:

MATE Act Training Requirement

As of 2023, all DEA prescribers must complete 8 hours of training on substance use disorder and pain management before DEA license renewal. This one-time requirement applies to both psychiatrists and PMHNPs.

Exemptions: Board-certified addiction psychiatrists and addiction medicine specialists (their board certification counts as meeting the requirement).

X-Waiver Elimination

Good news: The DATA 2000 ‘X-waiver’ requirement for prescribing buprenorphine was eliminated in 2023. Any DEA-registered psychiatrist or PMHNP can now prescribe buprenorphine for opioid use disorder without a special waiver.

But you must complete the MATE Act training (above) to maintain your DEA registration.

PDMP Requirements

Nearly every state now mandates checking the Prescription Drug Monitoring Program before prescribing controlled substances. Requirements vary:

• New York, Pennsylvania, Illinois: Check before every opioid or benzodiazepine prescription
• California: Check before first Schedule II–IV prescription and every 4 months during treatment
• Texas: Check before opioids, benzos, barbiturates, or carisoprodol
• Florida: Check before any controlled substance for patients 16+

Many states now participate in PMP Interconnect, allowing you to see if a patient received controlled medications in neighboring states. This is essential for telehealth providers working across state lines.

Electronic Prescribing

Federal law (SUPPORT Act) requires e-prescribing for Medicare controlled substances. Most states have their own e-prescribing mandates:

• New York: All prescriptions (since 2016)
• California: All prescriptions (since 2022)
• Pennsylvania, Illinois, Florida, Texas: Controlled substances (various effective dates 2019-2023)

For telehealth providers, e-prescribing is essentially mandatory anyway—your platform should have DEA-compliant e-prescribing with two-factor authentication built in.

Common Telehealth Prescribing Mistakes to Avoid

Based on recent enforcement actions and medical board disciplinary cases:

1. Online questionnaire-only evaluations: Washington state sanctioned a psychiatrist for prescribing after patients only filled out online forms without a real-time consultation. Always conduct a live video evaluation.

2. Inadequate documentation: If you’re prescribing controlled substances via telehealth, document thoroughly: history, mental status exam, rationale for medication choice, discussion of risks, treatment plan, and follow-up schedule.

3. Ignoring state-specific rules: Just because federal DEA rules allow something doesn’t mean your state does. Example: Texas’s prohibition on NP Schedule II prescribing, Florida’s requirement for psychiatric indications.

4. Not checking PDMPs: This is often mandatory and always good practice. Failing to check the PDMP can be grounds for board discipline if a patient is doctor-shopping or misusing medications.

5. Treating out-of-state patients without proper licensure: You need a medical license (or valid compact license, or state-specific telehealth registration) for every state where patients are located. No exceptions.

6. Audio-only consultations for controlled substances: While some states allow audio-only for follow-ups or specific situations (like buprenorphine during COVID), initiating controlled substance treatment with a new patient via telephone alone is risky. Use video.

What to Do Now: Preparing for Regulatory Changes

Short-term (through 2026):

• Continue practicing under the current DEA extension
• Ensure you’re compliant with PDMP requirements in every state where you practice
• Use electronic prescribing for all controlled substances
• Document telehealth evaluations thoroughly
• Complete MATE Act training if you haven’t already

Medium-term (2026-2027):

• Watch for DEA’s final rules on special telemedicine registration
• Budget for potential new DEA registration fees and compliance costs
• Plan for possible in-person exam requirements after certain time periods (e.g., 6 months for buprenorphine)
• Consider whether to pursue special telemedicine registration if you prescribe Schedule II substances

Long-term (practice building):

• For psychiatrists: You have the most flexibility. If you’re building a telehealth practice, obtain licenses in multiple states where demand is high. Consider platforms that handle patient acquisition so you can focus on clinical care rather than marketing.

• For PMHNPs: Understand your state’s scope of practice limitations. If you’re in a restricted state, you may need a collaborative physician. If you’re in a full-practice state, you have the same opportunities as psychiatrists for most psychiatric conditions (but watch for any stimulant prescribing limitations).

• For platforms: If you’re building or joining a telehealth service, ensure robust compliance infrastructure: multi-state licensure tracking, PDMP integration, e-prescribing, and clear protocols for when in-person referrals are needed.

Why Klarity Health Makes Sense for Psychiatric Providers

Here’s the reality of building a telehealth practice in 2026: regulatory compliance is complex, patient acquisition is expensive, and administrative overhead can quickly eat into your income.

Klarity Health removes these barriers:

Regulatory compliance built in:

• Multi-state licensure support and tracking
• DEA-compliant e-prescribing integrated
• HIPAA-secure platform
• Documentation systems designed for controlled substance prescribing

Patient acquisition without the risk:

• Pay only when patients book appointments (no upfront marketing spend)
• Pre-qualified patients matched to your specialty
• Both insurance and cash-pay patient flow
• No wasted advertising budget on clicks that don’t convert

Practice on your terms:

• Set your own schedule and availability
• Treat patients from multiple states (with appropriate licensure)
• Focus on clinical care instead of marketing and platform management
• Built-in telehealth infrastructure means no separate technology costs

Whether you’re a psychiatrist looking to scale beyond your local market or a PMHNP seeking to build a telehealth practice within your state’s scope, platforms that handle the business side let you focus on what you do best: treating patients.

The Bottom Line

Can you prescribe controlled substances via telehealth in 2026? Yes—with the right licensure, compliance protocols, and understanding of both federal DEA rules and your state’s specific requirements.

The temporary DEA extension through December 2026 gives you breathing room, but permanent rules are coming. The proposed special telemedicine registration could provide a long-term path for psychiatrists to continue telehealth-only practices for ADHD and other conditions requiring Schedule II medications.

But navigating multi-state licensure, PDMP requirements, e-prescribing mandates, and varying scope-of-practice laws for PMHNPs is complex. That’s exactly why the smart move is partnering with a platform that handles compliance and patient acquisition, letting you focus on delivering quality psychiatric care.

Ready to expand your telehealth practice without the regulatory headaches and marketing gamble? Explore how Klarity Health’s provider network gives you qualified patients, built-in compliance, and pay-per-appointment economics that guarantee ROI.

Frequently Asked Questions

Can I prescribe Adderall via telehealth to a new patient I’ve never met in person?

Yes, under current federal rules (extended through December 31, 2026), you can prescribe Schedule II stimulants like Adderall to new patients via real-time audio-video consultation without a prior in-person exam. However, you must follow state-specific rules: check your state’s PDMP, ensure you have proper licensure where the patient is located, and document the evaluation thoroughly. Some states have additional requirements—for example, Florida allows this only for psychiatric disorder treatment, and Texas NPs cannot prescribe Schedule II at all for outpatient care.

What’s the difference between what a psychiatrist and PMHNP can prescribe via telehealth?

Psychiatrists have full prescribing authority for all controlled substances in every state (with proper licensure and DEA registration). PMHNPs face state-dependent restrictions: in full-practice states like New York (after 3,600 hours) or California (phasing in), experienced NPs can prescribe the same controlled substances as psychiatrists. In restricted states like Texas, PMHNPs cannot prescribe Schedule II substances for outpatient psychiatric care. In reduced-practice states like Pennsylvania, NPs need physician collaboration and may face quantity limits on Schedule II prescriptions. Always check your specific state’s scope-of-practice laws.

Do I need separate DEA registrations for each state where I practice telehealth?

Yes. Controlled substance prescriptions are considered to occur where the patient is located, so you need a DEA registration in each state where you treat patients and prescribe controlled medications. You’ll need to register a physical address in each state (often your practice location or a designated office) and pay separate DEA registration fees. Many multi-state telehealth providers maintain licenses and DEA registrations in 5-10 states to maximize their patient reach.

What happens when the current DEA extension expires at the end of 2026?

The DEA is expected to finalize permanent telemedicine prescribing rules before the December 31, 2026 expiration. These rules will likely include a special telemedicine registration process that allows qualified prescribers (including board-certified psychiatrists) to continue prescribing Schedule II substances via telehealth without in-person exams. For buprenorphine, the proposed rule allows up to 6 months of treatment via telehealth before requiring an in-person visit. Providers should watch for the final rules publication (expected mid-to-late 2026) and budget for potential new registration fees and compliance requirements.

Is audio-only (telephone) consultation sufficient for prescribing controlled substances via telehealth?

Generally, no. Current DEA guidance expects real-time audio-visual (video) consultation to establish the telemedicine encounter for prescribing most controlled substances to new patients. The main exception is buprenorphine for opioid use disorder, where audio-only was permitted during COVID and the proposed permanent rule would continue allowing it. For follow-up appointments with established patients (especially those previously seen in person), some states permit telephone consultations, but for initiating treatment with new patients—particularly for Schedule II substances like stimulants—always use video to meet the standard of care and comply with federal expectations.

How much does it actually cost to acquire psychiatric patients through my own marketing?

Real all-in patient acquisition cost for psychiatric patients through DIY marketing typically runs $200-500+ per booked patient when you account for: SEO agency fees ($1,500-3,000/month), 6-12 months before meaningful results, Google Ads costs ($15-40+ per click for mental health keywords with low conversion rates), directory fees (Psychology Today, Zocdoc monthly subscriptions plus per-booking charges), staff time for lead qualification, no-show rates, and failed campaign testing. Many solo providers spend $3,000-5,000/month on marketing with uncertain ROI. Pay-per-appointment platforms eliminate this risk by charging only when qualified patients actually book, providing guaranteed ROI versus gambling on marketing channels.

Sources

1. U.S. Department of Health and Human Services. ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026.’ January 2, 2026. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. U.S. Drug Enforcement Administration. ‘DEA Announces Three New Telemedicine Rules to Continue Open Access to Critical Care.’ January 16, 2025. https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

3. Florida Statutes §456.47: Use of telehealth to provide services. 2025 edition. http://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0456/Sections/0456.47.html

4. Akerman LLP. ‘Harmonizing Federal and Florida Laws on Prescribing Controlled Substances Through Telehealth.’ March 2023. https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html

5. Texas Medical Board. ‘Prescriptive Authority FAQs and Supervision Requirements.’ Updated 2024. https://www.tmb.texas.gov/resources/for-applicants-and-licensees/prescribing-and-supervision

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=WASHINGTON%E2%80%94JANUARY%202%2C%202026%E2%80%94The%20U,while%20permanent%20rules%20are%20finalized
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=Expansion%20of%20Buprenorphine%20Treatment%20via,Telemedicine%20Encounter
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=For%20the%20first%20time%20online,being%20of%20patients
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=In%20developing%20these%20rules%2C%20DEA,person%20by%20the%20medical%20provider
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=telehealth%20to%20prescribe%20schedules%20III,one%20of%20the%20following%20categories
• https://www.jdsupra.com/legalnews/states-and-feds-signal-big-changes-to-9301791/#:~:text=of%20Ohio%E2%80%99s%20new%20telehealth%20prescribing,substance%20use%20disorder%20treatment%2C%20is
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=No%20special%20registration%20is%20required,the%20State%20to%20do%20so
• https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state#:~:text=,start%20their%20own%20medical%20practices